Design, synthesis and preliminary biological evaluation of new [1,2,3]triazolo[4,5-d]pyrimidine/thiourea hybrids as antiproliferative agents. 2017

Zhong-Hua Li, and Xue-Qi Liu, and Tao-Qian Zhao, and Peng-Fei Geng, and Wen-Ge Guo, and Bin Yu, and Hong-Min Liu
Key Laboratory of Advanced Drug Preparation Technologies (Zhengzhou University), Ministry of Education; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, PR China; Key Laboratory of Henan Province for Drug Quality and Evaluation, PR China.

A series of new [1,2,3]triazolo[4,5-d]pyrimidine/thiourea hybrids were designed and synthesized through the scaffold replacement/ring cleavage strategy. SARs studies revealed that the N-heteroarene moiety attached to the thiourea is preferred over the phenyl ring for the R2 substituents, while the hydrophobic aromatic group is beneficial for improving the activity. Among these compounds, compound 5r significantly inhibited cell growth of lung cancer cell lines H1650 and A549 (IC50 = 1.91, 3.28 μM, respectively), but was less toxic against the normal cell line GES-1 (IC50 = 27.43 μM). Mechanistic studies showed that compound 5r could remarkably inhibit the colony formation of H1650 cells, induced apoptosis possibly through the intrinsic apoptotic pathways, and arrested the cell cycle at G2/M phase. Our studies suggest that the [1,2,3]triazolo[4,5-d]pyrimidine/thiourea hybrids are a new class of chemotypes possessing interesting antiproliferative activity against lung cancer cells and could be potentially utilized for designing new antitumor agents.

UI MeSH Term Description Entries
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013890 Thiourea A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Zhong-Hua Li, and Xue-Qi Liu, and Tao-Qian Zhao, and Peng-Fei Geng, and Wen-Ge Guo, and Bin Yu, and Hong-Min Liu
June 2017, Bioorganic & medicinal chemistry letters,
Zhong-Hua Li, and Xue-Qi Liu, and Tao-Qian Zhao, and Peng-Fei Geng, and Wen-Ge Guo, and Bin Yu, and Hong-Min Liu
December 2019, Steroids,
Zhong-Hua Li, and Xue-Qi Liu, and Tao-Qian Zhao, and Peng-Fei Geng, and Wen-Ge Guo, and Bin Yu, and Hong-Min Liu
March 2020, Heliyon,
Zhong-Hua Li, and Xue-Qi Liu, and Tao-Qian Zhao, and Peng-Fei Geng, and Wen-Ge Guo, and Bin Yu, and Hong-Min Liu
November 2014, Molecules (Basel, Switzerland),
Zhong-Hua Li, and Xue-Qi Liu, and Tao-Qian Zhao, and Peng-Fei Geng, and Wen-Ge Guo, and Bin Yu, and Hong-Min Liu
January 2011, Scientia pharmaceutica,
Zhong-Hua Li, and Xue-Qi Liu, and Tao-Qian Zhao, and Peng-Fei Geng, and Wen-Ge Guo, and Bin Yu, and Hong-Min Liu
October 2014, European journal of medicinal chemistry,
Zhong-Hua Li, and Xue-Qi Liu, and Tao-Qian Zhao, and Peng-Fei Geng, and Wen-Ge Guo, and Bin Yu, and Hong-Min Liu
June 2014, European journal of medicinal chemistry,
Zhong-Hua Li, and Xue-Qi Liu, and Tao-Qian Zhao, and Peng-Fei Geng, and Wen-Ge Guo, and Bin Yu, and Hong-Min Liu
March 2015, Bioorganic & medicinal chemistry letters,
Zhong-Hua Li, and Xue-Qi Liu, and Tao-Qian Zhao, and Peng-Fei Geng, and Wen-Ge Guo, and Bin Yu, and Hong-Min Liu
March 1983, Journal of medicinal chemistry,
Zhong-Hua Li, and Xue-Qi Liu, and Tao-Qian Zhao, and Peng-Fei Geng, and Wen-Ge Guo, and Bin Yu, and Hong-Min Liu
February 2021, Molecules (Basel, Switzerland),
Copied contents to your clipboard!